Avacta Group (AIM: AVCT) closes oversubscribed £10m placing at 9.35% discount as AVA6103 enters clinical dosing

Avacta Group plc (AIM: AVCT), the London-headquartered clinical-stage biopharmaceutical company, has completed an oversubscribed equity raise of £10 million gross proceeds through a placing of 15,000,000 new ordinary shares and a director subscription for a further 873,016 shares, all priced at 63 pence per share. The fundraise was launched after market close on 26 March 2026 and closed the same evening, with the result announced on 27 March 2026. The 9.35 per cent discount to the 69.5 pence closing price on 25 March 2026 reflects both the urgency of the capital requirement and the strength of investor demand, with the placing being oversubscribed. Admission of the new shares to AIM is targeted for 7 April 2026, after which the enlarged share capital will stand at 456,288,511 ordinary shares.

Why is Avacta Group raising £10 million now and what does the capital timeline mean for shareholders?

The fundraise is not a distress raise. Avacta entered 2026 with £16.9 million in cash following its year-end position and has since been consuming capital across two active clinical programs. The £10 million gross proceeds are expected to extend the company’s cash runway into early Q1 2027, a runway the board considers sufficient to carry the company through several catalysts that management believes will be transformative for the pipeline’s commercial value.

The most immediate of those catalysts is AVA6103, the company’s second pre|CISION peptide drug conjugate, which is based on exatecan, a topoisomerase I inhibitor. The Phase 1a trial has opened for dosing, and Avacta anticipates preliminary data from this study in late 2026. The board’s stated rationale for raising now, ahead of those data, is to ensure the company retains 100 per cent ownership of AVA6103 through the initial readout, preserving optionality on partnership terms at a point when the program’s value should be better understood by potential counterparties.

That logic is coherent from a capital allocation standpoint. Clinical-stage oncology companies that out-license assets before Phase 1 data typically receive significantly lower upfront and milestone payments than those that can negotiate from an initial proof-of-concept position. The £10 million cost of maintaining that optionality is, in effect, a bet on AVA6103 data being positive enough to justify a materially higher partnership valuation in 2027 compared with what might be achievable today.

What is the pre|CISION platform and how does AVA6103 differentiate from antibody drug conjugates currently in development?

The pre|CISION platform is Avacta’s proprietary drug delivery architecture built around fibroblast activation protein, or FAP, a protease that is substantially overexpressed in most solid tumour microenvironments but is largely absent from healthy tissue. The platform designs peptide drug conjugates that remain pharmacologically inert in systemic circulation and are cleaved by FAP at the tumour site, releasing the cytotoxic payload locally. The design intent is to allow higher dose optimisation than would be tolerable with conventional antibody drug conjugates, which rely on different targeting and release mechanisms.

AVA6103 carries exatecan as its payload, the same topoisomerase I inhibitor that underpins Daiichi Sankyo and AstraZeneca’s blockbuster DXd antibody drug conjugate franchise. Exatecan is considered among the most potent topoisomerase I inhibitors in clinical development, but its use in earlier-generation formulations was limited by severe systemic toxicity. Avacta’s pre|CISION delivery is designed to address that toxicity ceiling, and the company’s preclinical pharmacology data, presented at scientific conferences in 2025, demonstrated a sustained-release payload delivery profile that the company argues compares favourably with marketed antibody drug conjugates on key pharmacokinetic parameters.

The clinical validation of that comparison is the central question the Phase 1a trial of AVA6103 is designed to answer. The trial also serves as a test for the platform’s underlying mechanism at a payload potency level and molecular weight distinct from the company’s lead asset, faridoxorubicin. If the preclinical profile translates, it would support the platform’s claims of broad applicability across multiple payload chemistries and tumour types.

How is faridoxorubicin Phase 1b progressing and what data should investors expect in the first half of 2026?

Faridoxorubicin, designated AVA6000 and a pre|CISION-enabled reformulation of doxorubicin, remains Avacta’s most clinically advanced asset. The Phase 1b expansion cohorts have nearly completed enrolment across three tumour types: salivary gland cancer, triple negative breast cancer, and soft tissue sarcoma. These cohorts represent a deliberate strategic choice, with Avacta targeting cancer types where existing treatment options carry poor prognosis and where doxorubicin activity is established but cardiac toxicity and lifetime dose limitations have historically constrained its therapeutic utility.

The company expects to release additional Phase 1a and Phase 1b data in the first half of 2026, including updated efficacy signals from the lead salivary gland cancer cohort and cardiac safety data that the board states led to the removal of faridoxorubicin’s lifetime maximum dosing restriction. If validated in the published data package, the removal of that dosing ceiling would be a material clinical differentiation point, as it directly addresses one of the most significant practical limitations of doxorubicin-based regimens.

Salivary gland cancer is an underserved indication with no approved targeted therapy and historically poor outcomes in the recurrent or metastatic setting. A meaningful response rate from a relatively well-tolerated regimen in this population would generate substantial interest from oncology-focused acquirers and licensing partners, particularly given the broader market’s appetite for differentiated oncology assets following a period of significant deal activity in the peptide drug conjugate and antibody drug conjugate space.

What does the oversubscribed placing reveal about institutional investor positioning in Avacta Group ahead of pivotal data?

The oversubscription of the placing is the most commercially significant detail in the two regulatory announcements. Avacta launched an accelerated bookbuild on 26 March 2026 seeking approximately £10 million and closed it the same evening, suggesting the book was covered quickly. The fact that demand exceeded supply at a 9.35 per cent discount to the prevailing market price indicates that investors with knowledge of the clinical programs were prepared to take dilution at current levels rather than wait for a secondary market opportunity.

The director participation reinforces that signal. Richard Hughes, a non-executive director and majority shareholder and director of sole broker Zeus Capital, subscribed for £500,000 worth of shares at the issue price. David Bryant, also a non-executive director, subscribed for £50,000. Together the two directors committed approximately £550,000 through the subscription, representing roughly 5.5 per cent of the total raise. These subscriptions constitute related party transactions under Rule 13 of the AIM Rules for Companies and were approved by the independent directors following consultation with Strand Hanson, the nominated adviser. Zeus Capital itself also participated in the placing, acquiring 317,476 shares for approximately £0.2 million.

On the market side, Avacta’s share price had recovered materially from its 52-week low of approximately 27.25 pence, trading at 69.5 pence on 25 March 2026, the day before the launch announcement. The 52-week high stands at approximately 83.20 pence. The placing price of 63 pence therefore sits within the trading range established over the past year, below recent market levels but representing a stock that has already gained approximately 66 per cent over the preceding twelve months. Analyst consensus as of late March 2026 points to a target price of approximately 83.25 pence, implying around 20 per cent upside from the pre-announcement price, and the two analysts covering the stock carry a buy recommendation.

How do the Zeus Capital warrant arrangements affect Avacta’s fully diluted share count and what terms apply?

Alongside the fundraise itself, the placing triggered a warrant obligation that Avacta had agreed with Zeus Capital when the broker was originally appointed. The arrangement stipulated that on raising a cumulative £20 million through Zeus Capital, the company would issue warrants representing 1.0 per cent of the issued share capital at the time of issue at the price of a future capital raise. Having crossed the £20 million fundraising threshold, Avacta has agreed to issue Zeus Capital with warrants over 4,364,457 ordinary shares, representing 0.96 per cent of the enlarged share capital following the placing and subscription.

The warrants are exercisable at 63 pence per share, matching the placing issue price, and carry a five-year life expiring on 7 April 2031. Zeus Capital has provided a lock-up undertaking preventing disposal of any shares acquired through warrant exercise before 7 April 2027, after which disposals must be conducted in consultation with Avacta. The warrant issuance itself is conditional upon admission becoming effective. On a fully diluted basis, the warrants add modestly to the capital structure but the exercise price is at a level that would only generate meaningful dilution if Avacta’s share price recovers toward or above current market levels, which is itself a positive condition for existing shareholders.

What are the execution risks for Avacta if the AVA6103 Phase 1a data readout is delayed or disappointing in late 2026?

The fundraise’s stated cash runway extends only to early Q1 2027, a narrow window that creates significant dependence on the AVA6103 data readout occurring broadly on schedule in late 2026. Clinical trials in early-phase oncology are routinely subject to enrolment delays, dose-escalation holds, and protocol amendments, any of which could push the initial readout into 2027 and potentially require the company to return to capital markets in a position of weaker leverage.

A disappointing Phase 1a data package, particularly one suggesting the FAP-mediated release mechanism is not generating the anticipated tumour concentrations or safety profile, would raise fundamental questions about the platform’s broader applicability and would likely re-price the stock toward the lower end of its recent trading range. In that scenario, the early Q1 2027 cash runway would likely prove insufficient to sustain the company’s research and development programs, and a further capital raise at a materially lower price cannot be ruled out.

The board’s decision to retain all rights to AVA6103 rather than execute a partnership ahead of data is therefore a calculated risk. The upside is a significantly stronger negotiating position if the data are positive. The downside is a more constrained capital position heading into 2027 if data are delayed or negative. The company’s existing faridoxorubicin data package and the planned 1H 2026 update provide a partial hedge, as positive faridoxorubicin data could support partner interest and capital structure options that are not contingent on AVA6103 performance.

How does Avacta’s fundraise and pipeline strategy compare with the broader peptide drug conjugate and oncology delivery sector?

Avacta occupies a specific and contested niche in the oncology delivery landscape. The broader field is dominated by antibody drug conjugates, where Daiichi Sankyo, AstraZeneca, and Pfizer have committed billions in partnering and acquisition activity. Peptide drug conjugates represent a structurally simpler and potentially lower-cost alternative manufacturing route, but the clinical validation base is substantially smaller, and investor and partner appetite for PDC platforms is heavily dependent on each company demonstrating that the tumour-selective release mechanism performs in patients as it does in preclinical models.

Avacta’s pre|CISION approach, with its reliance on FAP-mediated cleavage, offers a mechanistic rationale for tumour selectivity that is grounded in well-established tumour biology. FAP overexpression in the tumour microenvironment is documented across a wide range of solid tumour types, providing a theoretical basis for platform breadth. The company’s pipeline roadmap includes AVA6207, described as the first dual-payload peptide drug conjugate, which if successful would represent a meaningful differentiation from both conventional ADC and single-payload PDC approaches. Candidate selection for AVA6207 is expected in late 2026 or early 2027, meaning the fundraise proceeds are intended to carry Avacta to a point where it has three distinct clinical or near-clinical assets, each demonstrating the platform’s versatility.

The competitive pressure comes not only from ADC developers but also from other FAP-targeting approaches in oncology, including FAP-targeted radioligand therapies and bispecific antibodies. If any of these modalities demonstrates superior clinical outcomes in overlapping tumour types, it could constrain the commercial positioning of pre|CISION-based assets. Avacta’s management appears aware of this dynamic, given the emphasis on mechanistic differentiation in its investor communications, but the clinical data in 2026 will ultimately determine whether the platform’s preclinical advantages translate into a credible competitive position.

Key takeaways on what Avacta Group’s oversubscribed £10m fundraise means for investors, the pipeline, and the oncology delivery sector

• Avacta Group raised £10 million gross through an oversubscribed accelerated bookbuild on 26 March 2026, priced at 63 pence per share, a 9.35 per cent discount to the prior close of 69.5 pence.
• The oversubscription in a single evening signals strong institutional conviction in the pipeline ahead of pivotal data, with demand appearing to clear quickly at a below-market price.
• Net proceeds extend the company’s cash runway to early Q1 2027, timed to cover the anticipated late 2026 preliminary data readout from the AVA6103 (FAP-Exd) Phase 1a trial.
• Avacta is retaining 100 per cent ownership of AVA6103 through the initial data read, a strategy that preserves partnership optionality but increases financing risk if data are delayed or negative.
• Director subscriptions totalling approximately £550,000 from two non-executive directors signal board-level conviction at current market levels, though related party transaction requirements applied.
• Zeus Capital receives warrants over 4,364,457 shares at 63 pence, exercisable through 7 April 2031, with a one-year disposal restriction following admission, modestly adding to the fully diluted share count.
• Faridoxorubicin Phase 1b enrolment in salivary gland cancer, triple negative breast cancer, and soft tissue sarcoma is nearly complete, with a 1H 2026 data update including cardiac safety findings that enabled removal of the lifetime dosing cap.
• AVA6103 carries exatecan, the same payload class as the DXd platform used in Daiichi Sankyo and AstraZeneca’s blockbuster antibody drug conjugates, positioning Avacta in direct conversation with validated oncology partnering activity.
• The 52-week trading range of approximately 27.25 pence to 83.20 pence illustrates the binary, data-driven nature of AVCT as an investment, with the placing price sitting within the middle of that range.
• The cash runway to early Q1 2027 leaves limited margin for clinical or enrolment delays, making the H2 2026 AVA6103 data readout the single most important near-term event for the company’s capital position and partnership strategy.